Member Info for ogm4

Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire

https://pmlive.com/pharma_news/roches-genentech-enters-765m-autoimmune-disease-partnership-with-repertoire/

Article by Emily Kimber

24th April 2025

Share price seems to have bottomed out currently, i.e. flat line around 2.50p for the last 3 weeks or so. Let's hear what the board has to say, rather curious to hear the latest developments. Tim was talking about a few deals to be concluded this year and some surprise from the left whatever that means. This year was going to be the year it is all coming together.

Share price holding out reasonably well, considering it was only around 1.15p in January.

It is indeed about time we get another update. I am rather curious to hear what will be the next step in the chain of developments.

Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma Biotech, said:"These results are extremely compelling. Not only do they validate our MOA, they also indicate that P140 has the possibility to become a central treatment for a number of autoimmune diseases. Patients can be very hopeful, I certainly am!"

We could even see a bit of a bidding war I guess, depending on what the majors would want to put on the table for P140 and Immu's patents.

Patents, patients and patience needed!...

In fact the current market cap is very little just over 10 million pounds, absoluteley peanuts in pharma land.

Anyone ever been involved in these sort of deals working for or with C&P departments knows there is a dedicated step by step process to follow, which indeed takes its time.

I rather have absolute radio silence adhered to until a deal is being announced, than unlike some companies have done in the past tweeting minor info left, right and center with no real purpose sometimes it seems.

S&P 500 closing +9.5% higher

Tomorrow

We could see a bit of a bounce again, as the US markets surge again after Trump relaxing some of the tariffs and announcing a 90 day pause.

On a Monday where the markets were in deep red, IMM however closed in blue

Look at the staggering amounts of funding

Just a bit of Friday fun read...

https://www.labiotech.eu/best-biotech/immunology-biotech-companies/

Good morning,

I feel the tide is about to turn over the next few weeks.

Also expecting an update shortly of where we stand.

I believe what Tim earlier said is that P140 doesn't suppress the immune system, but instead puts it back in balance, whatever that means

I've bought a few more today ;-)

Incanthera doesn't bother me too much really tbh.

Tim and board need to focus on Immupharma, on its latest breakthrough developments and ongoing discussions.

It's a relatively safe way forward for IMM: No additional upfront payments at this stage, they still have 6 months to exercise them if they see fit at 70/30 ratio or simply decline them at no additional penalties.

Https://x.com/RoastPR/status/1906954897519501346